Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2023 07:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersBDC-1001 administered to initial...
July 31, 2023 17:27 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
May 25, 2023 17:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with...
May 11, 2023 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023BDC-1001 Phase 2 program expected to initiate...
April 26, 2023 10:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trialsREDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage...
March 29, 2023 16:15 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safetyBDC-1001 advances into a...
March 29, 2023 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumabData...
March 14, 2023 16:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
February 28, 2023 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the...
February 01, 2023 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at February Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment...